Hepion Pharmaceuticals
HEPA
HEPA was delisted on the 12th of May, 2025.
28 hedge funds and large institutions have $4.24M invested in Hepion Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 6 closing their positions.
1,218% more call options, than puts
Call options by funds: $145K | Put options by funds: $11K
10% less funds holding
Funds holding: 31 → 28 (-3)
13% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 8
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
56% less capital invested
Capital invested by funds: $9.74M → $4.24M (-$5.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$89.9K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$37.5K |
| 3 |
VF
Virtu Financial
New York
|
+$19.2K |
| 4 |
Jane Street
New York
|
+$14.2K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$8.33K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$143K |
| 2 |
Two Sigma Advisers
New York
|
-$30K |
| 3 |
State Street
Boston,
Massachusetts
|
-$29.1K |
| 4 |
Goldman Sachs
New York
|
-$19K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$18.3K |
HEPA Hedge Fund Activity: Q2 2022 in Review
28 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q2 2022, worth a combined $4.24M — down 56% from $9.74M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of HEPA and 3 opened new positions — a net loss of 3 holders — while 8 trimmed existing stakes and 7 added.
The largest buyer was Renaissance Technologies, adding an estimated $89.9K. The largest seller was Ikarian Capital, cutting an estimated $143K.
- 28 institutional investors held Hepion Pharmaceuticals (HEPA) as of Q2 2022, down from 31 in Q1 2022.
- Funds reported $4.24M of Hepion Pharmaceuticals stock for Q2 2022, down 56% quarter-over-quarter.
- 3 funds opened new Hepion Pharmaceuticals positions in Q2 2022 and 6 closed out, a net change of -3 holders.
- The largest Hepion Pharmaceuticals buyer in Q2 2022 was Renaissance Technologies, an estimated $89.9K added.
- The largest Hepion Pharmaceuticals seller in Q2 2022 was Ikarian Capital, an estimated $143K sold.
Based on aggregated 13F filings for Q2 2022.